Inkhabar webdesk

Oct 6 (Reuters) – Century Aluminum Co: * CENTURY ALUMINUM SIGNS POWER AGREEMENT EXTENSION WITH SANTEE COOPER THROUGH 2031 * CENTURY ALUMINUM CO – PLANS $50 MILLION INVESTMENT TO RESTART IDLE CAPACITY, BOOST PRODUCTION & INCREASE OVERALL U.S. ALUMINUM OUTPUT * CENTURY ALUMINUM CO – EXPANSION TO CREATE OVER 100 NEW JOBS Source text: Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

Oct 7 (Reuters) – Rio Tinto Ltd: * ROBE RIVER JV INVEST $733M TO EXTEND WEST ANGELAS * RIO TINTO, MITSUI AND NIPPON STEEL TO INVEST TO DEVELOP WEST ANGELAS SUSTAINING PROJECT * PROJECT RECEIVED ALL NECESSARY STATE AND FEDERAL GOVERNMENT APPROVALS * DEPOSITS WILL MAINTAIN WEST ANGELAS HUB'S TOTAL ANNUAL PRODUCTION CAPACITY OF 35 MILLION TONNES Further company coverage:

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

(Adds quote, context on policy in paragraphs 3-7) By Roberto Samora SAO PAULO, Oct 6 (Reuters) – Brazil may not be able to raise the mandatory biodiesel mix in diesel to 16% from 15% within a government-set deadline of March 2026, an official from the Brazilian Ministry of Mines and Energy said on Monday. Marlon Arraes, director of biofuels at the ministry, said during an industry event in Sao Paulo that there may not be enough time for the government to finalize the needed studies to implement the measure. "It’s possible that we won't be able to meet the March deadline. It’s highly challenging," Arraes said, adding the government has yet to finalize a report to be able to implement the new phase of the policy. Brazilian law mandates a gradual increase in the biodiesel mix of one percentage point per year, potentially reaching 20% by 2030. The official declined to give a timeline for introduction of the 16% mandatory mix. The potential postponement of the deadline would mainly impact the soybean oil industry, as the oilseed is used to produce more than 75% of Brazil's biodiesel. The 15% mix, which was supposed to become mandatory in March this year, was only implemented in August, with the country's government citing inflation concerns. According to the official, the legislation requires that any increase in the blend be conditioned on technical feasibility studies, which are ongoing. (Reporting by Roberto Samora in Sao Paulo; Writing by Andre Romani and Fernando Cardoso; Editing by Nia Williams and Lincoln Feast.)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

CLASSIFIED JUSTICE DEPARTMENT OPINION AUTHORIZES STRIKES ON SECRET LIST OF CARTELS -CNN

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)

(Adds valuations and financial details in paragraph 5, funding in paragraph 6) Oct 6 (Reuters) – MapLight Therapeutics, a clinical-stage biotech backed by Novo Holdings, said on Monday it is targeting a valuation of up to $704.3 million in its U.S. initial public offering, amid a rebound in investor appetite for new issues. The Redwood City, California-based firm plans to raise $250.8 million by offering 14.8 million shares priced at $17 apiece. The stock is expected to trade on the Nasdaq under the ticker symbol "MPLT." U.S. IPO activity has picked up in recent months, reversing a slowdown from earlier in the year — when trade-policy uncertainty curbed momentum — as recent listings have attracted strong investor demand. Last month, biotech firm LB Pharmaceuticals was received warmly on its debut. MapLight is developing drugs for central nervous system disorders, especially schizophrenia and Alzheimer's disease psychosis, autism spectrum disorder and Parkinson's disease. The company reported a net loss of $52.2 million for the six months ended June 30, compared with a net loss of $37.3 million a year earlier. In July, MapLight raised about $372.5 million in a funding round co-led by Forbion and Life Sciences at Goldman Sachs Alternatives. Morgan Stanley, Jefferies, Leerink Partners and Stifel are the underwriters for the offering. (Reporting by Prakhar Srivastava in Bengaluru; Editing by Sahal Muhammed and Alan Barona)

(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)